These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1069 related items for PubMed ID: 19448588

  • 1. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May 18; 51(1312):38-9. PubMed ID: 19448588
    [Abstract] [Full Text] [Related]

  • 2. Once-daily mesalamine granules for ulcerative colitis.
    Lawlor G, Ahmed A, Moss AC.
    Expert Rev Clin Immunol; 2010 Jul 18; 6(4):521-6. PubMed ID: 20594123
    [Abstract] [Full Text] [Related]

  • 3. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
    Kao J, Kwok K, Das KM.
    J Clin Gastroenterol; 2010 Sep 18; 44(8):531-5. PubMed ID: 20495466
    [Abstract] [Full Text] [Related]

  • 4. Extended-release mesalamine granules for ulcerative colitis.
    Love BL, Miller AD.
    Ann Pharmacother; 2012 Nov 18; 46(11):1529-36. PubMed ID: 23115226
    [Abstract] [Full Text] [Related]

  • 5. Once-daily mesalamine (Lialda) for ulcerative colitis.
    Med Lett Drugs Ther; 2007 Mar 26; 49(1257):25-6. PubMed ID: 17375030
    [No Abstract] [Full Text] [Related]

  • 6. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H.
    Clin Gastroenterol Hepatol; 2009 Jul 26; 7(7):762-9. PubMed ID: 19375519
    [Abstract] [Full Text] [Related]

  • 7. MMX mesalamine.
    Baker DE.
    Rev Gastroenterol Disord; 2006 Jul 26; 6(3):146-52. PubMed ID: 16957657
    [Abstract] [Full Text] [Related]

  • 8. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S, Kamm MA, Lichtenstein GR.
    Expert Rev Gastroenterol Hepatol; 2008 Jun 26; 2(3):299-314. PubMed ID: 19072380
    [Abstract] [Full Text] [Related]

  • 9. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S.
    Gastroenterology; 2010 Apr 26; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [Abstract] [Full Text] [Related]

  • 10. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
    Osterman MT, Lichtenstein GR.
    Methods Find Exp Clin Pharmacol; 2009 Apr 26; 31(1):41-6. PubMed ID: 19357797
    [Abstract] [Full Text] [Related]

  • 11. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2006 Apr 26; 6(2):97-105. PubMed ID: 16699478
    [Abstract] [Full Text] [Related]

  • 12. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P.
    Am J Gastroenterol; 2012 Jul 26; 107(7):1064-77. PubMed ID: 22565161
    [Abstract] [Full Text] [Related]

  • 13. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan 26; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 14. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD, Das KM.
    J Clin Gastroenterol; 2006 Aug 26; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK.
    Am J Gastroenterol; 2002 Jun 26; 97(6):1398-407. PubMed ID: 12094857
    [Abstract] [Full Text] [Related]

  • 16. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
    Zhu Y, Tang RK, Zhao P, Zhu SS, Li YG, Li JB.
    Eur J Gastroenterol Hepatol; 2012 May 26; 24(5):487-94. PubMed ID: 22465970
    [Abstract] [Full Text] [Related]

  • 17. New lessons: classic treatments, expanding options in ulcerative colitis.
    Hanauer SB.
    Colorectal Dis; 2006 May 26; 8 Suppl 1():20-4. PubMed ID: 16594960
    [Abstract] [Full Text] [Related]

  • 18. Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
    Horst SN, Kane S.
    Expert Opin Pharmacother; 2012 Oct 26; 13(15):2225-32. PubMed ID: 22970981
    [Abstract] [Full Text] [Related]

  • 19. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
    Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, Savarino V, Sturniolo GC, Vecchi M, Ardia A, Bellinvia S.
    Aliment Pharmacol Ther; 2009 Nov 01; 30(9):908-18. PubMed ID: 19678813
    [Abstract] [Full Text] [Related]

  • 20. Does treatment schedule matter? Once daily versus divided doses of 5-ASAs.
    Kane S.
    Dig Dis; 2010 Nov 01; 28(3):478-82. PubMed ID: 20926875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.